Week 4: Lecture 4
## Immunostimulation: Enhancing the Immune System for Therapeutic Utility
Main Takeaway: While immunosuppression dampens the immune system for autoimmune diseases or transplant rejection, immunostimulation aims to enhance immune responses to fight infections, cancer, and explore novel therapeutic strategies for chronic conditions like addiction and hypertension by leveraging the adaptive immune system's power.
### I. Introduction to Immunomodulation
* Recap (Pre-recorded Lecture): Immunosuppression – dampening the immune system for:
Preventing transplant rejection*.
Treating autoimmune disease*.
Managing chronic inflammatory disease*.
* Current Lecture Focus: Immunostimulation – enhancing the immune system's ability for:
Recognizing and clearing cancer cells*.
Clearing pathogens* (infections).
Interfering with other pathological mechanisms*.
### II. Immunostimulatory Therapies Overview
* Key Areas to Cover:
1. Vaccines and Adjuvants.
2. Recombinant Cytokines and Growth Factors.
3. Antibody Therapies.
4. Cellular Therapies (e.g., CAR T cells).
### III. Vaccines and Adjuvants
* Pioneer: Edward Jenner – pioneered smallpox vaccine using cowpox (unethical by modern standards, but groundbreaking).
* Modern Successes:
* SARS-CoV-2 mRNA vaccines: Dramatically increased investment and innovation in mRNA technology.
* Gardasil (HPV vaccine): Developed by Ian Fraser, protects against cancers caused by HPV.
* Evolution of Vaccine Types:
* Early Crude Vaccines: Killed bacteria/viruses.
* Live Attenuated Viruses: Organisms with poor human replicative ability, providing strong exposure without severe disease.
* Virus-Like Particles (VLPs): Mimic viral structure (e.g., Gardasil), strong immune primer.
* Proteins and Peptides: Simpler, but often less effective without adjuvants, due to lack of long-lived protection.
* mRNA and DNA Vaccines: Significant investment post-SARS-CoV-2 success.
* The Role of Adjuvants:
* Immune System Requirement: Needs signals that something is both foreign AND dangerous.
* Danger Signal Sources:
* PAMPs (Pathogen-Associated Molecular Patterns): From bacteria/viruses, recognized by pattern recognition receptors (e.g., Toll-like receptors).
* DAMPs (Danger-Associated Molecular Patterns): Released during cell death/necrosis.
* Adjuvant Function: Replicate these danger signals to drive strong, long-lived immune responses with memory.
* Examples of Adjuvants:
* CPG motifs: Nucleic acid sequences common in bacterial genomes, activate Toll-like receptors.
* Lipids: Found in infectious organisms, activate Toll-like receptors.
* Metal oxides (Alum): Aluminium potassium sulphate, an ancient and common adjuvant.
* Mechanism (Recent Insight): Alum complexes the foreign antigen and stimulates dendritic cells. This involves immunoreceptor tyrosine-based activation (ITA) pathways (similar to IGE receptor, but via other immunoreceptors). This activates Syk (Sick) in dendritic cells, encouraging antigen uptake and expression of co-stimulatory molecules. This leads to enhanced T cell activation.
* Vaccines for Cancer:
* Challenges: Cancer cells are "self," making unique targeting difficult.
* Most Success: Eliminating infectious organisms that drive cancer.
* HPV vaccine for cervical and other cancers.
* Hepatitis vaccines for liver cancers.
* Ongoing Efforts: Developing direct anti-cancer vaccines, especially with renewed interest in mRNA technology.
### IV. Recombinant Cytokines and Growth Factors
* Recombinant Cytokines (e.g., Interleukin 2 - IL-2):
* Application: Boosting T cell responses in cancer.
* Mechanism: If T cells recognize cancer but are ineffective, IL-2 can drive proliferation and differentiation of activated T cells into cytotoxic effectors.
* Recombinant Growth Factors (e.g., Granulocyte Colony Stimulating Factor - G-CSF):
* Application: Providing innate immune protection in chemotherapy patients.
* Mechanism: Chemotherapy can devastate bone marrow, reducing immune cells (e.g., neutrophils). G-CSF boosts neutrophil numbers, providing fundamental protection against infection.
### V. Antibody Therapies as Immunostimulants
* A. Broad Protection: Intravenous Immunoglobulin (IVIG) / Subcutaneous Immunoglobulin (SCIG)
* Mechanism: Pooled antibodies purified from plasma donations provide broad coverage against diverse infectious organisms.
* Application: Treating primary immunodeficiencies (e.g., genetic polymorphisms in lymphocyte genes), where patients have low antibody levels and are prone to infection.
* Administration: Historically intravenous (IVIG), now also subcutaneous (SCIG).
* B. Specific Targeting in Cancer Therapy
* Principle: Cancer cells often upregulate expression of particular surface proteins, providing a target for specific antibodies.
* Mechanisms of Action:
1. Complement Activation: Antibody binding can fix complement, leading to the complement cascade, membrane attack complex (MAC) formation, and cellular lysis.
2. Effector Cell Recruitment (ADCC): Antibodies bind to the target cell; their Fc part then binds to Fc receptors on immune effector cells, driving cell-mediated cytotoxicity.
* Bi-specific Antibodies:
* Concept: One arm recognizes one overexpressed tumor marker, the other arm recognizes a second overexpressed tumor marker.
* Benefit: Increases selectivity, reduces off-target effects.
* Example: Amivanamab – used in certain cancers, targets two tumor markers, driving cellular cytotoxicity.
* Checkpoint Inhibitors:
* Context: Immune checkpoints are pathways that dampen T cell responses (evolved to prevent autoimmunity/chronic inflammation). Cancer cells exploit these to evade immune attack.
* Mechanism: Antibodies block these inhibitory pathways, "taking the brakes off" the immune system.
* Examples:
* CTLA-4 Blockade:
Normally, CD80/86 binding to CTLA-4 on T cells leads to negative signaling and T cell inhibition (immunosuppression, e.g., by Balatace*).
* Ipilimumab is an antibody that blocks CTLA-4. This prevents the negative signal, thereby encouraging productive T cell signaling, proliferation, and differentiation into effector functions (immunostimulation).
* PD-1 / PDL-1 Blockade:
* Tumor cells express PDL-1 which engages with PD-1 on T cells, leading to a negative signal and T cell inhibition.
* Antibodies block either PD-1 or PDL-1, removing this braking mechanism and allowing effective T cell activation against cancer.
* Success: Significant breakthrough in metastatic melanoma and currently in many clinical trials as adjunct therapy.
* Rituximab:
* Target: CD20 surface molecule, overexpressed on B cell lymphoma cells.
* Mechanism: Binds CD20, activating both complement cascade (leading to lysis) and effector cells (cell-dependent cytotoxicity).
* Other Strategies with Antibodies:
* Antibody-Drug Conjugates: Tag antibodies with cytotoxic chemicals for localized delivery to cancer cells, minimizing off-target effects of chemotherapy.
* Radionuclide Conjugates: Deliver radionuclides to cancer cells for selective radiation killing.
### VI. Cellular Therapies
* A. Tumour Infiltrating Lymphocytes (TILs):
* Process:
1. Biopsy tumor.
2. Isolate immune cells (TILs) from the tumor (presumed to recognize tumor).
3. Expand TILs ex vivo.
4. Reintroduce expanded TILs into the patient.
* Goal: TILs hone to the tumor and mediate anti-tumor action.
* Nature: Highly personalized medicine, expensive but effective (e.g., in advanced melanoma, showing marked reduction in tumor size compared to ipilimumab in some studies).
* B. Chimeric Antigen Receptor (CAR) T Cells:
* Process:
1. T cells are taken from a patient.
2. T cells are transduced with a chimeric antigen receptor (CAR) construct.
3. The CAR has an extracellular domain (like an antibody domain) that recognizes a specific tumor antigen (e.g., CD19).
4. This domain is linked to a transmembrane region and an intracellular signaling domain containing ITA motifs (immunoreceptor tyrosine-based activation motifs).
5. These modified T cells are expanded ex vivo.
6. Reintroduced into the patient.
* Mechanism: When CAR T cells engage with the tumor antigen, the ITA motifs are activated, driving T cell activation and anti-tumor responses.
* Nature: Highly personalized, very expensive, but enormously effective in some cancers, leading to remission.
### VII. Harnessing the Immune System for Chronic Conditions (Ambitious Therapies)
* Concept: Generating vaccines for non-infectious, non-cancer chronic conditions.
* Examples:
* Hypertension: Modulating the angiotensin II system for long-term blood pressure reduction.
* Alzheimer's Disease.
* Drug Addiction (Cocaine Vaccine as a Case Study):
* Problem: Addictive drugs (e.g., cocaine, fentanyl) are small molecules, typically invisible to the immune system. They produce a "high" by entering the Central Nervous System (CNS).
* Strategy:
1. Chemically conjugate the small drug molecule (e.g., cocaine) to a foreign, immunogenic protein.
2. Administer this conjugate with an adjuvant.
3. Goal: Generate antibodies that can bind to free cocaine in the bloodstream, preventing it from reaching the CNS and producing a "high."
* Target Patient: Highly motivated individuals trying to quit, to prevent relapse due to the "high."
* Pre-clinical Evidence:
* Rats: Cocaine-conjugated vaccine reduced cocaine-induced locomotor activity significantly and for a sustained period.
* Non-human Primates: Using a radiolabeled tracer that binds to dopamine transporters (where cocaine also binds), vaccinated animals showed far less displacement of the tracer by cocaine, indicating less cocaine entry into the brain.
* Clinical Trials: Human clinical safety trials are encouraging. Focus on motivated individuals. Potential for similar strategies against fentanyl.
* Limitations: Possible to overwhelm antibody protection by taking more of the drug; not a solution for everyone.
### VIII. Learning Outcomes
1. Understand situations where immunostimulation is necessary/useful.
2. Describe and provide examples of vaccines, adjuvants, cytokines, antibodies, and cells as immunostimulants, focusing on those enhancing immune actions.
3. Appreciate how a deep understanding of the immune system can lead to ambitious therapeutic strategies beyond traditional cancer or infectious disease treatments.